147 related articles for article (PubMed ID: 37558474)
1. Hodgkin Lymphoma-related Inflammatory Modification-displayed Castleman Disease-like Histological Features and Positron Emission Tomography/Computed Tomography Usefulness for the Differential Diagnosis.
Yamauchi H; Momoki M; Kamiyama Y; Gunji T; Yokoyama H; Saito T; Boutboul D; Oksenhendler E; Yano S
Intern Med; 2024 Apr; 63(7):993-998. PubMed ID: 37558474
[TBL] [Abstract][Full Text] [Related]
2. Colonic Castleman Disease on FDG PET/CT.
Li F; Xiao L; Cai H; Li L
Clin Nucl Med; 2023 Jan; 48(1):71-72. PubMed ID: 35961369
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET/ CT for initial staging and response assessment in Castleman disease - retrospective single-center study of 29 cases.
Koukalová R; Selingerová I; Řehák Z; Adam Z; Szturz P
Klin Onkol; 2021; 34(2):120-127. PubMed ID: 33906360
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of
Takano K; Yajima R; Kamekura R; Yamamoto M; Takahashi H; Yama N; Hatakenaka M; Himi T
Laryngoscope; 2018 May; 128(5):1120-1125. PubMed ID: 28988418
[TBL] [Abstract][Full Text] [Related]
5. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?
Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S
Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169
[TBL] [Abstract][Full Text] [Related]
6. Correlations between maximum standardized uptake value measured via
Li H; Wang X; Zhang L; Yi X; Qiao Y; Jin Q
J Cancer Res Ther; 2019; 15(7):1581-1588. PubMed ID: 31939441
[TBL] [Abstract][Full Text] [Related]
7. FDG PET/CT Findings in TAFRO Syndrome.
Hotta M; Minamimoto R; Yashima A; Nakano M; Yamashita H
Clin Nucl Med; 2018 Nov; 43(11):828-829. PubMed ID: 30222681
[TBL] [Abstract][Full Text] [Related]
8. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
9. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.
El-Galaly TC; d'Amore F; Mylam KJ; de Nully Brown P; Bøgsted M; Bukh A; Specht L; Loft A; Iyer V; Hjorthaug K; Nielsen AL; Christiansen I; Madsen C; Johnsen HE; Hutchings M
J Clin Oncol; 2012 Dec; 30(36):4508-14. PubMed ID: 23150698
[TBL] [Abstract][Full Text] [Related]
10. Combined positron emission tomography/computed tomography for diagnosis and monitoring of orbital adnexal lymphoma.
Klingenstein A; Garip-Kuebler A; Mueller-Lisse UG; Hintschich C
Acta Ophthalmol; 2018 Sep; 96(6):e712-e717. PubMed ID: 30146694
[TBL] [Abstract][Full Text] [Related]
11.
He L; Chen Y; Tan X; Sun X; Zhang Q; Luo H; Jiang L
Jpn J Radiol; 2023 Jan; 41(1):98-107. PubMed ID: 35895223
[TBL] [Abstract][Full Text] [Related]
12. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
13. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
[TBL] [Abstract][Full Text] [Related]
14. Correlation of mean apparent diffusion coefficient (ADC) and maximal standard uptake value (SUVmax) evaluated by diffusion-weighted MRI and 18F-FDG-PET/CT in children with Hodgkin lymphoma: a feasibility study.
Rosbach N; Fischer S; Koch V; Vogl TJ; Bochennek K; Lehrnbecher T; Mahmoudi S; Grünewald L; Grünwald F; Bernatz S
Radiol Oncol; 2023 Jun; 57(2):150-157. PubMed ID: 37341195
[TBL] [Abstract][Full Text] [Related]
15. Comparison of bone marrow biopsy and fluorodeoxyglucose-positron emission tomography for the assessment of bone marrow infiltration in children with Hodgkin's lymphoma.
Arslantaş E; Ayçiçek A; Akıcı F; Özkara S; Yılmaz B; Özdemir N; Bayram C
Nuklearmedizin; 2023 Feb; 62(1):20-26. PubMed ID: 36746148
[TBL] [Abstract][Full Text] [Related]
16. Classic Hodgkin lymphoma and Castleman disease: an entity appears to be emerging.
Lyapichev KA; You MJ; Vega F; Solis LM; Medeiros LJ
Virchows Arch; 2020 Sep; 477(3):437-444. PubMed ID: 32152665
[TBL] [Abstract][Full Text] [Related]
17. Utility of
Jitani AK; Dutta S; Mandal PK; De R; Jajodia E; Baul S; Chakrabarti P; Dolai TK
Indian J Med Res; 2021 May; 154(5):691-698. PubMed ID: 35532587
[TBL] [Abstract][Full Text] [Related]
18. (18) F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma.
Ujjani CS; Hill EM; Wang H; Nassif S; Esposito G; Ozdemirli M; Cordova C; Cheson BD
Br J Haematol; 2016 Aug; 174(3):410-6. PubMed ID: 27098364
[TBL] [Abstract][Full Text] [Related]
19. PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial.
Picardi M; Cavaliere C; Della Pepa R; Nicolai E; Soricelli A; Giordano C; Pugliese N; Rascato MG; Cappuccio I; Campagna G; Cerchione C; Vigliar E; Troncone G; Mascolo M; Franzese M; Castaldo R; Salvatore M; Pane F
Ann Hematol; 2021 Jun; 100(6):1525-1535. PubMed ID: 33909101
[TBL] [Abstract][Full Text] [Related]
20. Italian Multicenter Study on Accuracy of
Cistaro A; Cassalia L; Ferrara C; Quartuccio N; Evangelista L; Bianchi M; Fagioli F; Bisi G; Baldari S; Zanella A; Pillon M; Zucchetta P; Burei M; Sala A; Guerra L; Guglielmo P; Burnelli R; Panareo S; Scalorbi F; Rambaldi I; Piccardo A; Garaventa A; Familiari D; Fornito MC; Lopci E; Mascarin M; Altini C; Ferrari C; Perillo T; Santoro N; Borsatti E; Rubini G
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):e267-e273. PubMed ID: 29739722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
